Edition:
United Kingdom

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

37.20USD
12 Dec 2018
Change (% chg)

-- (--)
Prev Close
$37.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
218,268
52-wk High
$61.25
52-wk Low
$34.95

Latest Key Developments (Source: Significant Developments)

Supernus Announces Positive Results From Two Phase III Studies For SPN-812 In Children With ADHD
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Supernus Pharmaceuticals Inc ::SUPERNUS ANNOUNCES POSITIVE RESULTS FROM TWO PHASE III STUDIES FOR SPN-812 IN CHILDREN WITH ADHD.SUPERNUS PHARMACEUTICALS INC - EACH STUDY, P301 AND P303, MET PRIMARY ENDPOINT WITH ROBUST STATISTICAL SIGNIFICANCE.SUPERNUS PHARMACEUTICALS INC - EACH STUDY SHOWED EFFICACY ON BOTH HYPERACTIVITY/IMPULSIVITY AND INATTENTION SUBSCALES WITH STATISTICAL SIGNIFICANCE.SUPERNUS PHARMACEUTICALS INC - P301 STUDY SHOWED STATISTICALLY SIGNIFICANT ONSET OF ACTION AS EARLY AS WEEK 1 ON BOTH TREATMENT DOSES.SUPERNUS PHARMACEUTICALS INC - SPN-812 WAS WELL-TOLERATED WITH LOW INCIDENCE OF ADVERSE EVENTS AND LOW DISCONTINUATION RATES.SUPERNUS PHARMACEUTICALS INC - EXPECTS TO ANNOUNCE TOPLINE DATA FROM STUDY P302, FIRST ADOLESCENT PHASE III TRIAL OF SPN-812, BY END OF DECEMBER 2018.SUPERNUS PHARMACEUTICALS INC - TOPLINE DATA FROM SECOND ADOLESCENT PHASE III TRIAL, P304, ARE EXPECTED BY END OF Q1 OF 2019.SUPERNUS PHARMACEUTICALS INC - EXPECTS TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR SPN-812 IN SECOND HALF OF 2019.  Full Article

Supernus Q3 Gaap Earnings Per Share $0.52
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Supernus Pharmaceuticals Inc ::SUPERNUS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND RECORD QUARTERLY REVENUE.Q3 GAAP EARNINGS PER SHARE $0.52.Q3 REVENUE $103 MILLION VERSUS I/B/E/S VIEW $100.6 MILLION.Q3 EARNINGS PER SHARE VIEW $0.41 -- THOMSON REUTERS I/B/E/S.SEES 2018 NET PRODUCT SALES OF $388 MILLION TO $395 MILLION.SEES 2018 OPERATING EARNINGS OF $120 MILLION TO $125 MILLION.FY2018 EARNINGS PER SHARE VIEW $1.85, REVENUE VIEW $398.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Supernus announces third quarter 2017 financial results
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Supernus Pharmaceuticals Inc :Supernus announces third quarter 2017 financial results.Q3 earnings per share $0.29.Q3 earnings per share view $0.27 -- Thomson Reuters I/B/E/S.Sees full year 2017 net product sales guidance range to $290 million to $295 million​.Sees ‍FY 2017 operating income in range of $85 million to $90 million​.  Full Article

UPDATE 3-Supernus Pharma's ADHD treatment fails to impress; shares fall

Dec 6 Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals.